MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Study produces ‘promising results’ for Carthera’s SonoCloud tech for mild Alzheimer’s symptoms

Study produces ‘promising results’ for Carthera’s SonoCloud tech for mild Alzheimer’s symptoms

By

Carthera SonoCloud Alzheimer's
[Image from Carthera’s website]
Carthera announced positive results from a trial evaluating the safety and efficacy of the use of its SonoCloud technology.

Results from the investigator-sponsored trial of SonoCloud in patients with mild Alzheimer’s Disease (AD) were published this week in the Alzheimer’s Research & Therapy Journal.

Paris-based Carthera designed SonoCloud, an implantable 1 MHz ultrasound device, to be activated on-demand using a transdermal needle connected to an external interface. The company said in a news release that the platform, which delivers low-intensity pulsed ultrasound (LIPU) to temporarily disrupt the blood-brain barrier (BBB), reduced β-amyloid and tau pathologies and improved cognitive performance in Alzheimer’s preclinical models.

Professor Alexandre Carpentier and Dr. Stéphane Epelbaum conducted a translational study at Hôpital de la Pitié-Salpêtrière (AP-HP Sorbonne, Paris, France) that follows previous trials displaying Sonocloud’s potential. The aim of the study was to demonstrate the safety of the technology in patients with mild AD, as well as to explore whether ultrasound alone could reduce their amyloid load.

In the trial, patients with mild AD had a single-emitter version of the SonoCloud implanted under local anesthesia to target the left supramarginal gyrus. Seven ultrasound sessions — lasting approximately 10 minutes each — over three and a half months were performed twice per month on nine patients to temporarily disrupt the BBB.

PET imaging was performed at inclusion and at four and eight months after initial sonications to monitor brain metabolism and amyloid levels. The trial showed that SonoCloud can disrupt the BBB in Alzheimer’s patients and it further confirmed the safety previously demonstrated in patients with brain tumors.

Additionally, researchers observed a slight decrease in amyloid load in the majority of patients despite the short treatment and observation window, which Carthera said demonstrates the therapeutic potential of the modality previously observed in preclinical models.

“We’re currently planning a clinical trial that will lead to marketing authorization of the SonoCloud for the treatment of glioblastoma while also continuing to explore this technology in a greater number of brain indications in combination with various therapeutic agents,” Carthera CEO Frédéric Sottilini said in the release. “The outcomes of this study reinforce our conviction that the SonoCloud has the potential to unlock the efficacy of therapies for brain diseases that were previously untreatable.”

In case you missed it

RSS From Medical Design & Outsourcing

  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]
  • Medtronic’s VC leader discusses risk, returns, strategy and an ‘ugly truth’
    A panel of medtech investors convened today for DeviceTalks Boston included David Neustaedter, VP of venture capital at Medtronic (NYSE: MDT). He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company. (Read more in his DeviceTalks speaker bio.) Medtronic has more than $500 million in… […]
  • Here’s where Harvard’s engineering dean sees medtech research going
    Surgical robotics, artificial intelligence, and combatting climate change are but some of the priorities that have Harvard’s engineering school dean excited. Speaking today at DeviceTalks Boston, Frank J. Doyle III described the Harvard John A. Paulson School of Engineering and Applied Sciences as a “well-kept secret” historically. But Harvard engineering is staking out a strong position when it… […]
  • gBETA Medtech accelerator picks its next startups
    The gBETA Medtech virtual accelerator today named the five startups that will participate in the spring program leading up to the June 21 showcase day. The five startups for the spring 2022 cohort are: Mother of Fact: This mobile app for moms with babies offers nutrition tracking, preventative monitoring and daily coaching from licensed dietitians… […]
  • FDA warns of potential toxic risk from Fresenius hemodialysis machines
    The FDA is evaluating the risk of exposure to toxic chemicals from silicone tubing used in Fresenius Medical Care (NYSE: FMS) hemodialysis machines. The investigation concerns three models of Fresenius hemodialysis machines: the 2008T, 2008K2, and 2008K. The chemicals — non-dioxin-like (NDL) polychlorinated biphenyl acids (PCBAs) and NDL polychlorinated biphenyls (PCBs) — are in the… […]